A Phase II Study of Lenvatinib in Patients with Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Researchers in this study are evaluating the anticancer drug lenvatinib in patients with adenoid cystic carcinoma that has continued to grow, spread, or came back despite prior therapy. Lenvatinib works by inhibiting the growth of the blood vessels that tumors need to grow and spread.
Lenvatinib is already approved for treating thyroid and kidney cancer; its use in this study is considered investigational. It is taken orally (by mouth).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have adenoid cystic carcinoma that has continued to grow, spread, or came back despite prior treatment and cannot be successfully treated with surgery or radiation therapy.
- At least 2 weeks must pass between the completion of prior therapies and entry into the study (4 weeks for bevacizumab treatment).
- Patients must be able to walk and do routine activities for more than half of their normal waking hours.
- This study is for patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Alan L. Ho at 646-888-4235.